In VivoPharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com
ScripArcturus Therapeutics and licensing partner CSL have got approval in the EU for Kostaive, a self-amplifying mRNA (sa-mRNA) vaccine that the firms hope will become a major product in the COVID-19 space
Pink SheetA misinformation dispute in Japan over Arcturus Therapeutics' COVID-19 vaccine Kostaive (ARCT-154) saw an unprecedented twist in December, when local distributor Meiji Seika Pharma decided to pursue
Pink SheetA self-amplifying mRNA vaccine for COVID-19, Arcturus Therapeutics’ Kostaive (ARCT-154), has been the subject of extensive disparaging and scientifically inaccurate comments online in its first market